– Company has filed US patent on novel, brain-penetrating PDE2 and PDE10 inhibitors –
CNS company biocrea today announced it has filed a patent application covering its brain-penetrating inhibitors of phosphodiesterases. These compounds constitute a new generation of promising drug candidates to address several CNS disorders that are currently lacking effective treatment options. biocrea has submitted a patent application to the U.S. Patent Office (USPTO) covering compounds and uses of its proprietary PDE2 and PDE10 inhibitors.
While the inhibitors of PDE10 show excellent potential for the treatment of schizophrenia, Huntington’s disease and Tourette’s syndrome, the PDE2 inhibitors cover a whole spectrum of new biological activities and treatment opportunities. Moreover, biocrea’s brain-penetrating PDE2 inhibitors show promise for the treatment of drug-induced movement disorders.
biocrea’s patent application also comprises dual inhibitors of PDE2 and PDE10 as the combination of both modes of action in one molecule results in synergistic biological effects.
So far, validating the benefit of brain PDE inhibitors in CNS diseases has been difficult because access to brain PDEs is limited by the so-called “blood brain barrier” (BBB). The team of biocrea has overcome these limitations and developed brain-penetrating, highly specific PDE inhibitors that constitute a new generation of promising drug candidates for the treatment of CNS disorders. The most advanced compound of biocrea’s novel family of PDE inhibitors, a brain-penetrating, selective PDE2 inhibitor, has been selected to enter pre-clinical development.